Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has provided an announcement.
Onco-Innovations Limited has announced that Nucro-Technics Inc. has begun analytical development for its Polynucleotide Kinase Phosphatase (PNKP) technology, a crucial step in its preclinical program. This development involves creating advanced analytical methods using liquid chromatography–mass spectrometry to measure the PNKP inhibitor in preclinical samples, which is essential for future human clinical trials. The validated methods will support upcoming studies under Good Laboratory Practice standards, providing critical data for regulatory submissions and scientific insights into the drug’s behavior in the body, thereby advancing Onco’s DNA repair-targeting therapies.
More about Onco-Innovations Ltd.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company focuses on pioneering research and innovative solutions for the prevention and treatment of cancer, with an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 67,643
Technical Sentiment Signal: Strong Sell
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.